Andreas Tiran
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Andreas Tiran has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
Andreas H. Wagner
From the Department of Laboratory Medicine (A.T., H-J.G., B.T) and the Institute of Medical Biochemistry and Medical Molecular Biology (W.F.G.), University of Graz, Graz, Austria; the Department of Cardiovascular Physiology (A.H.W.), University of Goettingen, Goettingen, Germany; and the Department of Haematology (E.B.M.v.L.), University of Groningen, Groningen, the Netherlands
1 shared publicationBeate Tiran
From the Department of Laboratory Medicine (A.T., H-J.G., B.T) and the Institute of Medical Biochemistry and Medical Molecular Biology (W.F.G.), University of Graz, Graz, Austria; the Department of Cardiovascular Physiology (A.H.W.), University of Goettingen, Goettingen, Germany; and the Department of Haematology (E.B.M.v.L.), University of Groningen, Groningen, the Netherlands
1 shared publicationEllen B.M. van Leeuwen
From the Department of Laboratory Medicine (A.T., H-J.G., B.T) and the Institute of Medical Biochemistry and Medical Molecular Biology (W.F.G.), University of Graz, Graz, Austria; the Department of Cardiovascular Physiology (A.H.W.), University of Goettingen, Goettingen, Germany; and the Department of Haematology (E.B.M.v.L.), University of Groningen, Groningen, the Netherlands
1 shared publicationHans-Jürgen Gruber
From the Department of Laboratory Medicine (A.T., H-J.G., B.T) and the Institute of Medical Biochemistry and Medical Molecular Biology (W.F.G.), University of Graz, Graz, Austria; the Department of Cardiovascular Physiology (A.H.W.), University of Goettingen, Goettingen, Germany; and the Department of Haematology (E.B.M.v.L.), University of Groningen, Groningen, the Netherlands
1 shared publication- Wolfgang F. Graier
Gottfried Schatz Research Center, Medical University of Graz, Graz, Austria
1 shared publication
Latest Publications
- 1 July 2002
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 22 (7) , 1075-1080
Aspirin InhibitsChlamydia pneumoniae–Induced Nuclear Factor-κB Activation, Cytokine Expression, and Bacterial Development in Human Endothelial Cells
Objective— Chlamydia pneumoniaehas been associated with atherosclerosis. Infection of vascular endothelial cells withC pneumoniaeincreases the expression of proatherogenic cytokines mediated by nuclear factor (NF)-κB, a transcription factor. The present study was designed to test the effect of aspirin onC pneumoniae–induced NF-κB activation, interleukin expression, and bacterial development in cultured human endothelial cells. Methods and Results— Aspirin, its metabolite salicylic acid, and 2 other unrelated NF-κB inhibitors showed a strong concentration-dependent inhibitory effect on chlamydial growth, indicated by the reduction of bacterial inclusions and the titer of infectious progeny. Involvement of the transcription factor NF-κB was confirmed by electrophoretic mobility shift assay and by transfection experiments with appropriate decoy oligodeoxynucleotides. Attenuation of theC pneumoniae–induced activation of NF-κB by aspirin also reduced the secretion of interleukin-6 and interleukin-8, indicating efficient inhibition of NF-κB gene expression. Reduction of chlamydial growth was not caused by apoptosis of the host cell, as determined by monitoring characteristic chromatin condensation. Conclusions— These data provide evidence that NF-κB–mediated gene activation represents a crucial step in the developmental cycle ofC pneumoniae. Aspirin exerts an anti-chlamydial effect that is due to the inhibition ofC pneumoniae–induced NF-κB activation, which might account for some of the cardioprotective activity of aspirin.
- 1 July 2002
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 22 (7) , 1075-1080
Aspirin InhibitsChlamydia pneumoniae–Induced Nuclear Factor-κB Activation, Cytokine Expression, and Bacterial Development in Human Endothelial Cells
Objective— Chlamydia pneumoniaehas been associated with atherosclerosis. Infection of vascular endothelial cells withC pneumoniaeincreases the expression of proatherogenic cytokines mediated by nuclear factor (NF)-κB, a transcription factor. The present study was designed to test the effect of aspirin onC pneumoniae–induced NF-κB activation, interleukin expression, and bacterial development in cultured human endothelial cells. Methods and Results— Aspirin, its metabolite salicylic acid, and 2 other unrelated NF-κB inhibitors showed a strong concentration-dependent inhibitory effect on chlamydial growth, indicated by the reduction of bacterial inclusions and the titer of infectious progeny. Involvement of the transcription factor NF-κB was confirmed by electrophoretic mobility shift assay and by transfection experiments with appropriate decoy oligodeoxynucleotides. Attenuation of theC pneumoniae–induced activation of NF-κB by aspirin also reduced the secretion of interleukin-6 and interleukin-8, indicating efficient inhibition of NF-κB gene expression. Reduction of chlamydial growth was not caused by apoptosis of the host cell, as determined by monitoring characteristic chromatin condensation. Conclusions— These data provide evidence that NF-κB–mediated gene activation represents a crucial step in the developmental cycle ofC pneumoniae. Aspirin exerts an anti-chlamydial effect that is due to the inhibition ofC pneumoniae–induced NF-κB activation, which might account for some of the cardioprotective activity of aspirin.